Henry Schein, Inc.  

(Public, NASDAQ:HSIC)   Watch this stock  
Find more results for David Henry�
113.87
+0.37 (0.33%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 113.55 - 115.49
52 week 88.90 - 120.99
Open 113.75
Vol / Avg. 540,158.00/444,042.00
Mkt cap 9.74B
P/E 23.13
Div/yield     -
EPS 4.92
Shares 85.53M
Beta 0.74
Inst. own 95%
May 28, 2014
Henry Schein Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 Henry Schein Earnings Release (Estimated) Add to calendar
Mar 11, 2014
Henry Schein at Barclays Global Healthcare Conference - Webcast
Feb 12, 2014
Henry Schein at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Q4 2013 Henry Schein Earnings Conference Call - Webcast
Feb 11, 2014
Q4 2013 Henry Schein Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 5.18% 4.96%
Operating margin 7.40% 7.08%
EBITD margin - 8.42%
Return on average assets 9.64% 8.65%
Return on average equity 18.14% 15.99%
Employees 16,000 -
CDP Score - -

Address

135 Duryea Road
MELVILLE, NY 11747
United States - Map
+1-631-8435500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Henry Schein, Inc. is a provider of health care products and services to office-based practitioners. The Company conducts its business through two segments: healthcare distribution and technology. The healthcare distribution segment aggregates its dental, medical, animal health and international operating segments. This segment consists of consumable products, small equipment, laboratory products, large dental equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Its technology group provides software, technology and other services to healthcare practitioners, primarily in the United States, Canada, the United Kingdom, Australia and New Zealand. In April 2014, the Company acquired about 80% ownership position in Medivet.

Officers and directors

Stanley M. Bergman Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James P. Breslawski President, Chief Operating Officer, Director; Chief Executive Officer of Henry Schein Global Dental Group
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Steven Paladino Chief Financial Officer, Executive Vice President, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Steve Klis President - Henry Schein Global Practice Solutions
Bio & Compensation  - Reuters
Lonnie Shoff President and Chief Executive Officer of Global Animal Health and Strategic Partnerships Group
Age: 54
Bio & Compensation  - Reuters
Michael Zack President - International Group
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gerald A. Benjamin Chief Administrative Officer, Executive Vice President, Director
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark E. Mlotek Chief Strategic Officer, Executive Vice President, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James A. Harding Chief Technology Officer, Senior Vice President
Bio & Compensation  - Reuters
Leonard A. David Chief Compliance Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance